Adefovir

Caitlin Soto, PharmD, BCIDP, Janessa M. Smith, Pharm.D., BCPS
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID

INDICATIONS

FDA

  • Chronic hepatitis B in patients 12 years of age and older

NOTE: FDA-labeled indication is unchanged. The AASLD-IDSA 2026 practice guideline expanded HBV treatment eligibility broadly (e.g., immune-active disease, immune-tolerant patients over age 40), but adefovir is not among the recommended agents for any of these criteria.

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.